Robert A. Harrington

3.5k total citations · 1 hit paper
34 papers, 2.4k citations indexed

About

Robert A. Harrington is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Robert A. Harrington has authored 34 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Cardiology and Cardiovascular Medicine, 14 papers in Surgery and 5 papers in Internal Medicine. Recurrent topics in Robert A. Harrington's work include Antiplatelet Therapy and Cardiovascular Diseases (25 papers), Acute Myocardial Infarction Research (15 papers) and Lipoproteins and Cardiovascular Health (9 papers). Robert A. Harrington is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (25 papers), Acute Myocardial Infarction Research (15 papers) and Lipoproteins and Cardiovascular Health (9 papers). Robert A. Harrington collaborates with scholars based in United States, United Kingdom and Sweden. Robert A. Harrington's co-authors include Robert F. Storey, Steen Husted, Håkan Emanuelsson, Christopher P. Cannon, Gary Peters, Lars Wallentin, Stefan James, Benjamin M. Scirica, Philippe Gabríel Steg and Christopher P. Cannon and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Robert A. Harrington

32 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association

2020 223 citations Robert A. Harrington et al. Circulation profile →

Peers

Countries citing papers authored by Robert A. Harrington

Since Specialization

Citations

This map shows the geographic impact of Robert A. Harrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Harrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Harrington more than expected).

Fields of papers citing papers by Robert A. Harrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Harrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Harrington. The network helps show where Robert A. Harrington may publish in the future.

Co-authorship network of co-authors of Robert A. Harrington

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Harrington. A scholar is included among the top collaborators of Robert A. Harrington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Harrington. Robert A. Harrington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial 2025 ·Diabetes Care ·Gregory G. Schwartz, Michael Szarek, J. Wouter Jukema, Christa M. Cobbaert, (unknown), Vera Bittner, Markus Schwertfeger, Deepak L. Bhatt, Sergio Fazio, (unknown), Shaun G. Goodman, Robert A. Harrington, Harvey D. White, Philippe Gabríel Steg	5
2	Principles for the Future of Biomedical Research in the United States and Optimizing the National Institutes of Health: A Presidential Advisory From the American Heart Association 2025 ·Circulation ·Joseph C. Wu, Donna K. Arnett, Ivor J. Benjamin, Mark A. Creager, Robert A. Harrington, Joseph A. Hill, P. Michael Ho, (unknown), Stephanie Scarmo, Svati H. Shah, Gordon F. Tomaselli	0
3	The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis 2018 ·EuroIntervention ·Anne Bellemain-Appaix, (unknown), Deepak L. Bhatt, Kenneth Ducci, Robert A. Harrington, Matthew T. Roe, Stephen Wiviott, Michel Cucherat, Johanne Silvain, Jean‐Philippe Collet, François Bernasconi, Gilles Montalescot	22
4	Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial 2016 ·American Heart Journal ·Yuichi J. Shimada, Sameer Bansilal, Stephen D. Wiviott, Richard C. Becker, Robert A. Harrington, Anders Himmelmänn, Benjamin Neely, Steen Husted, Stefan James, Hugo A. Katus, Renato D. Lópes, Philippe Gabríel Steg, Robert F. Storey, Lars Wallentin, Christopher P. Cannon	22
5	TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROME: RESULTS FROM THE PLATO TRIAL 2013 ·Journal of the American College of Cardiology ·Daniel Lindholm, Christoph Varenhorst, Christopher P. Cannon, Robert A. Harrington, Anders Himmelmänn, Juan Maya, Steen Husted, Hugo Katus, Philippe Gabríel Steg, Robert F. Storey, Lars Wallentin, Stefan James	4
6	CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial 2013 ·Circulation ·Pierluigi Tricoci, Edmond Chen, Megan L. Neely, (unknown), Peggy H. Wong, Peter Sinnaeve, Lars Wallentin, Lisa K. Jennings, Robert F. Storey, Philip E. Aylward, Harvey D. White, Frans Van de Werf, Paul W. Armstrong, Claes Held, Marco Valgimigli, Robert A. Harrington, John Strony, Kenneth W. Mahaffey, David J. Moliterno	2
7	THE EFFICACY AND SAFETY OF TICAGRELOR AS COMPARED TO CLOPIDOGREL, WITH AND WITHOUT A GLYCOPROTEIN IIB/IIIA INHIBITOR IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS INTERVENTION: A PLATO (STUDY OF PLATELET INHIBITION AND PATIENT OUTCOMES) ANALYSIS 2013 ·Journal of the American College of Cardiology ·Sameer Bansilal, Stephen Wiviott, Richard C. Becker, Robert A. Harrington, Anders Himmelmänn, Benjamin Neely, Steen Husted, Robert F. Storey, Philippe Gabríel Steg, Hugo Katus, Stefan James, Lars Wallentin, Christopher P. Cannon	2
8	Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial 2012 ·Circulation ·Lars Wallentin, Stefan James, Evangelos Giannitsis, Hugo A. Katus, Richard C. Becker, Christopher P. Cannon, Jay Horrow, Steen Husted, Agneta Siegbahn, Philippe Gabríel Steg, Robert F. Storey, Lisa Wernroth, Robert A. Harrington	3
9	The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial 2011 ·Journal of the American College of Cardiology ·Benjamin M. Scirica, Christopher P. Cannon, Håkan Emanuelsson, Eric L. Michelson, Robert A. Harrington, Steen Husted, Stefan James, Hugo A. Katus, Prem Pais, Dimitar Raev, Jindřich Špinar, Philippe Gabríel Steg, Robert F. Storey, Lars Wallentin	92
10	Pulmonary Function in Patients With Acute Coronary Syndrome Treated With Ticagrelor or Clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] Pulmonary Function Substudy) 2011 ·The American Journal of Cardiology ·Robert F. Storey, Richard C. Becker, Robert A. Harrington, Steen Husted, Stefan James, Frank Cools, Philippe Gabríel Steg, Nardev S. Khurmi, Håkan Emanuelsson, Soo Teik Lim, Christopher P. Cannon, Hugo A. Katus, Lars Wallentin	54
11	Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes 2011 ·European Heart Journal ·Robert F. Storey, Richard C. Becker, Robert A. Harrington, Steen Husted, Stefan James, Frank Cools, Philippe Gabríel Steg, Nardev S. Khurmi, Håkan Emanuelsson, (unknown), Richard Cairns, Christopher P. Cannon, Lars Wallentin	133
12	TICAGRELOR DOES NOT AFFECT PULMONARY FUNCTION TESTS COMPARED TO CLOPIDOGREL IN ACUTE CORONARY SYNDROMES: RESULTS OF THE PLATO PULMONARY SUBSTUDY 2010 ·Journal of the American College of Cardiology ·Robert F. Storey, Richard C. Becker, Christopher P. Cannon, Frank Cools, Håkan Emanuelsson, Robert A. Harrington, Steen Husted, Stefan James, Hugo Katus, (unknown), Soo Teik Lim, Philippe Gabríel Steg, Lars Wallentin	2
13	THE INCIDENCE OF ARRHYTHMIAS AND CLINICAL ARRHYTHMIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES TREATED WITH TICAGRELOR OR CLOPIDOGREL IN THE PLATO TRIAL 2010 ·Journal of the American College of Cardiology ·Benjamin M. Scirica, Christopher P. Cannon, Håkan Emanuelsson, Robert A. Harrington, Steen Husted, Stefan James, Hugo Katus, Eric L. Michelson, (unknown), (unknown), Jindřich Špinar, Philippe Gabríel Steg, Robert F. Storey, Lars Wallentin, (unknown)	3
14	Changes in Inflammatory Biomarkers in Patients Treated With Ticagrelor or Clopidogrel 2010 ·Clinical Cardiology ·Steen Husted, Robert F. Storey, Robert A. Harrington, Håkan Emanuelsson, Christopher P. Cannon	39
15	Bleeding risk with AZD6140, a reversible P2Y₁₂receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial 2009 ·International Journal of Clinical Practice ·Steen Husted, Robert A. Harrington, Christopher P. Cannon, Robert F. Storey, Patrick Mitchell, Håkan Emanuelsson	13
16	Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome 2007 ·Journal of the American College of Cardiology ·Christopher P. Cannon, Steen Husted, Robert A. Harrington, Benjamin M. Scirica, Håkan Emanuelsson, Gary Peters, Robert F. Storey	391
17	Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes 2007 ·Journal of the American College of Cardiology ·Robert F. Storey, Steen Husted, Robert A. Harrington, S Heptinstall, Robert A. Wilcox, Gary Peters, Mark Wickens, Håkan Emanuelsson, Paul A. Gurbel, Peer Grande, Christopher P. Cannon	372
18	Glycoprotein receptor inhibitors in the management of acute coronary syndromes 2002 ·Current Cardiology Reports ·(unknown), Robert A. Harrington	1
19	Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes 1999 ·American Heart Journal ·Robert A. Harrington	17
20	Intraobserver and interobserver variability of the amniotic fluid index 1993 ·American Journal of Obstetrics and Gynecology ·Joseph P. Bruner, George Reed, Albert P. Sarno, Robert A. Harrington, (unknown)	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact